MSB related, does sound familiar?:
(Not a cross promote (demote), posted for information as stem cell related.)
"Athersys tries to post-hoc-analyze its way out of another trial fail for stroke stem cell therapy...
stem cell therapy has failed yet again. Then, as it’s done in the past, the company pivoted to a post-hoc analysis, picking out a subset of younger patients to show where their treatment had an effect. Even then, the results only approached but did not reach statistical significance." LINK
At least FDA can't be blamed this time.
Tread carefully mums/dads/newbies and DYOR.
Just sayin'.
Cell Therapy News/Articles, page-13547
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.12 |
Change
0.015(1.36%) |
Mkt cap ! $1.278B | |||
| Open | High | Low | Value | Volume |
| $1.13 | $1.16 | $1.10 | $7.169M | 6.411M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 7296 | $1.12 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.12 | 43068 | 1 |
View Market Depth
| Last trade - 16.10pm 08/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |